U.S. Other Utilities Stock News

NYSE:CCL
NYSE:CCLHospitality

Carnival Millions Launch And Ship Redeployment Reshape Onboard Revenue Story

Carnival Cruise Line, part of Carnival Corporation & (NYSE:CCL), has launched "Carnival Millions", described as the cruise industry's first fleetwide interactive lottery across its North American and European ships. The company is also redeploying the Carnival Adventure ship from Australia to North America, citing regulatory uncertainty and cost pressures in the Australian market. Carnival Corporation & (NYSE:CCL) is focusing on new onboard entertainment with Carnival Millions, a lottery...
NYSE:RRC
NYSE:RRCOil and Gas

Range Resources Links Higher Dividend And Decade Long Gas Contract For Visibility

Range Resources (NYSE:RRC) has approved an 11% increase to its dividend, reinforcing its focus on shareholder returns. The company has also entered into a 10 year natural gas supply agreement with a Midwest power plant, securing long term demand for its production. For investors watching NYSE:RRC, these two moves connect income and business stability. The stock trades at $39.09, with a value score of 3 and multi year returns that include 47.7% over 3 years and 292.0% over 5 years, which...
NYSE:CACI
NYSE:CACIProfessional Services

Is It Too Late To Consider CACI International (CACI) After Its Strong Multi‑Year Rally?

Wondering if CACI International at around US$597 per share still offers value, or if most of the opportunity has already been reflected in the price? The stock has had a mixed recent run, with a 1% gain over the last 7 days, a 7.2% decline over 30 days, an 11.1% return year to date, and a 77.9% return over the past year, following a 102.4% return over 3 years and 175.8% over 5 years. These moves have kept CACI on many investors' watchlists, as they reassess what is already priced in and what...
NasdaqGS:SVRA
NasdaqGS:SVRABiotechs

Assessing Savara (SVRA) Valuation After FDA Priority Review For MOLBREEVI

Savara (SVRA) is back in focus after the FDA accepted for review the biologics license application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis and granted it Priority Review with an August 22, 2026 action date. See our latest analysis for Savara. The FDA news arrives after a mixed few months for Savara, with a 1-day share price return of 2.23% and a 7-day share price return of 4.37%. However, the 90-day share price return shows a 5.09% decline, which contrasts with a...
NasdaqGS:INVA
NasdaqGS:INVAPharmaceuticals

Innoviva (INVA) One Off Gain Driven 65.9% Margin Challenges Bullish Earnings Narratives

Innoviva (INVA) has wrapped up FY 2025 with Q4 revenue of US$114.6 million and basic EPS of US$2.19, capping a trailing 12 month period where revenue was US$411.3 million and basic EPS reached US$4.02 alongside a reported net profit margin of 65.9% that was lifted by a US$161.6 million one off gain. Over the past few quarters, the company has seen revenue move from US$88.6 million in Q1 2025 to US$114.6 million in Q4 2025, while basic EPS shifted from a loss of US$0.74 in Q1 2025 to US$2.19...
NYSE:PACS
NYSE:PACSHealthcare

PACS Group ESOP Shelf Spurs Questions On Dilution And Staff Alignment

PACS Group (NYSE:PACS) has filed a large shelf registration tied to an employee stock ownership plan related common stock offering. The filing outlines a framework for issuing a substantial amount of common shares to support ESOP activity over time. This move is designed to connect employee compensation more directly with the company’s equity. PACS Group operates in the post acute care and senior living space, where staffing, retention, and alignment of incentives are central issues for...
NYSE:RDDT
NYSE:RDDTInteractive Media and Services

Reddit UK Child Data Fine Puts Compliance And Valuation In Focus

UK Information Commissioner's Office fines Reddit for failures in protecting children's personal data and privacy. Regulator cites insufficient age checks and risk assessments on the platform prior to January 2025. Reddit plans to appeal the decision, putting its data practices and user protections under closer scrutiny. For investors watching NYSE:RDDT, this case puts Reddit's content and data practices in the spotlight alongside its financial profile. The stock trades at $151.25, with a...
NasdaqGS:PI
NasdaqGS:PISemiconductor

A Look At Impinj (PI) Valuation After Cautious Guidance And Weaker Near Term Outlook

Impinj (PI) is back in focus after quarterly revenue landed in line with expectations, but management’s guidance for the coming quarter fell well short, citing inventory normalization, softer retail demand, and modest pricing pressure. See our latest analysis for Impinj. The weak guidance has already affected sentiment, with a 30 day share price return of negative 24.08% and a year to date share price return of negative 31.67%. At the same time, the 1 year total shareholder return is 34.37%,...
NYSE:HUBS
NYSE:HUBSSoftware

HubSpot Direct Mail Automation Launch Meets Rich Valuation And Weak Momentum

PostcardMania has launched an automated direct mail integration for HubSpot (NYSE:HUBS) users. The integration lets HubSpot customers trigger physical mailers directly from CRM workflows. The rollout connects digital campaigns with real world follow ups to address email saturation and engagement challenges. For HubSpot, which focuses on CRM, marketing automation and sales tools, this kind of direct mail automation fits into how many businesses already use the platform to manage the full...
NYSE:GSL
NYSE:GSLShipping

How Global Ship Lease’s US$0.625 Dividend Move Will Impact Global Ship Lease (GSL) Investors

Global Ship Lease recently went ex-dividend on February 24, 2026, entitling shareholders of record to receive a US$0.625 per share payout on March 6, 2026. This dividend timing and size can influence trading behavior, as some investors adjust positions around ex-dividend dates to pursue income-focused strategies. Now we’ll explore how this US$0.625 dividend and ex-dividend timing affect Global Ship Lease’s existing investment narrative and capital-return thesis. Invest in the nuclear...
NYSE:EIX
NYSE:EIXElectric Utilities

A Look At Edison International (EIX) Valuation After Analyst Caution Strong Results And Bond Offering

Edison International (EIX) is back in focus after a mix of cautious analyst calls, a US$549.1 million fixed income raise, and detailed 2025 results paired with fresh earnings guidance through 2027. See our latest analysis for Edison International. The recent mix of earnings guidance, fresh bond issuance and ongoing wildfire related headlines has come alongside strong momentum. A 30 day share price return of 18.75% and a 1 year total shareholder return of 53.96% suggest interest has been...
NYSE:NOMD
NYSE:NOMDFood

Nomad Foods (NYSE:NOMD) Margin Hit And Quarterly EPS Loss Challenge Bullish Profitability Narratives

Nomad Foods (NYSE:NOMD) closed FY 2025 with fourth quarter revenue of €773.1 million and a basic EPS loss of €0.07, capping a trailing twelve month revenue line of about €3.0 billion and EPS of €0.91 as margins compressed from a 7.3% net profit margin to 4.5% over the year. Over recent quarters, the company has seen quarterly revenue move from €793.4 million in Q4 2024 to €760.1 million in Q1 2025, €746.9 million in Q2 2025, €752.4 million in Q3 2025 and €773.1 million in Q4 2025. Basic EPS...
NasdaqGS:HBAN
NasdaqGS:HBANBanks

Is Huntington Bancshares (HBAN) Pricing Look Attractive After Recent Regional Bank Headlines

If you are wondering whether Huntington Bancshares is attractively priced at its current level, this article walks through what the numbers are really saying about the stock. The shares last closed at US$17.54, with a 7 day return of a 2.6% decline, a 30 day return of 2.8%, a year to date return of 0.3%, and a 1 year return of 10.6%, compared with 32.2% over 3 years and 34.9% over 5 years. Recent news coverage around regional banks has focused on how investors are weighing interest rate...
NYSE:VTR
NYSE:VTRHealth Care REITs

Is It Too Late To Consider Ventas (VTR) After Its Strong Multi‑Year Share Price Rally?

If you are wondering whether Ventas shares still offer value after a strong run, it becomes crucial to look closely at what you are paying for each dollar of cash flow and assets. The stock last closed at US$86.44, with returns of 1.1% over 7 days, 13.8% over 30 days, 11.8% year to date, 29.4% over 1 year, 99.7% over 3 years and 92.0% over 5 years. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage of Ventas has focused on its position...
NasdaqGS:GTM
NasdaqGS:GTMInteractive Media and Services

Is ZoomInfo Technologies (GTM) Now Attractively Priced After Steep Multi‑Year Share Price Declines

If you are wondering whether ZoomInfo Technologies' share price now reflects good value or lingering risks, you are not alone. That is exactly what this article will unpack for you. The stock recently closed at US$6.40, with returns of a 0.5% decline over 7 days, 26.6% decline over 30 days, 33.4% decline year to date, 46.7% decline over 1 year, 74.2% decline over 3 years, and 86.0% decline over 5 years. These figures raise clear questions about what investors are currently paying for. Recent...
NYSE:LYV
NYSE:LYVEntertainment

What Live Nation Entertainment (LYV)'s 2025 Profit Drop Amid Rising Sales Means For Shareholders

In February 2026, Live Nation Entertainment reported full-year 2025 sales of US$25,201.41 million, upaction from US$23,155.63 million a year earlier, while net income fell to US$495.97 million and continuing operations shifted to a basic and diluted loss per share of US$0.24. Despite weaker profitability, the company’s expanding global venue footprint and continued growth in concert-driven revenue have reinforced analyst optimism about its long-term positioning in live entertainment. With...
NYSE:EME
NYSE:EMEConstruction

Emcor Group (EME) Margin Expansion To 7.5% Tests Bearish Narratives

EMCOR Group (EME) closed out FY 2025 with fourth quarter revenue of US$4.5b and basic EPS of US$9.72, alongside net income excluding extra items of US$434.6m, setting a clear marker for its latest reporting season. The company reported quarterly revenue of US$3.8b and EPS of US$6.35 in Q4 2024, rising to US$4.5b and EPS of US$9.72 in Q4 2025. Trailing twelve month EPS was US$28.30 on revenue of US$17.0b, giving investors a results set that combines higher earnings, a 7.5% net margin and prior...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives

Intro TG Therapeutics (TGTX) just closed out FY 2025 with Q4 revenue of US$192.6 million and basic EPS of US$0.16, alongside trailing twelve month revenue of US$616.3 million and EPS of US$3.10. Over the past couple of years, the company has reported revenue increasing from US$83.9 million in Q3 2024 to US$192.6 million in Q4 2025. Quarterly basic EPS has ranged from US$0.03 in Q1 2025 to US$2.69 in Q3 2025 and US$0.16 in the latest quarter, framing this release as a check-in on how durable...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

A Look At Syndax Pharmaceuticals (SNDX) Valuation After Q4 Revenue Beat And Wider Loss

Syndax Pharmaceuticals (SNDX) just reported Q4 2025 results that paired revenue ahead of expectations with a wider loss, as Revuforj net revenue grew 38% and Niktimvo sales continued to build. See our latest analysis for Syndax Pharmaceuticals. At a share price of US$20.67, Syndax has seen a 4.29% 90 day share price return and a 35.27% total shareholder return over the past year, suggesting momentum has been building despite some recent short term softness. If this update on a cancer focused...
NYSE:PRG
NYSE:PRGConsumer Finance

PROG Holdings Raises Dividend While Reshaping Business After Partner Fallout

PROG Holdings (NYSE:PRG) announced a 7.7% increase in its quarterly dividend, signaling confidence in returning cash to shareholders. The company is managing revenue pressure tied to a weaker retail backdrop and the bankruptcy of a major partner. Management has tightened Progressive Leasing criteria and is leaning more on its buy now, pay later platform and recent acquisitions. PROG Holdings enters this phase of corporate change with its shares at $36.83 and a mixed return profile. The...
NasdaqGS:AVAV
NasdaqGS:AVAVAerospace & Defense

A Look At AeroVironment (AVAV) Valuation After The US$186 Million Switchblade Contract Win

AeroVironment (AVAV) drew fresh investor focus after securing a US$186 million delivery order from the U.S. Army for its next-generation Switchblade 600 Block 2 and 300 Block 20 loitering munitions. See our latest analysis for AeroVironment. Despite the new Army order and recent headlines around the BlueHalo acquisition and the CFO transition, AeroVironment’s 30 day share price return of 16.14% and 90 day return of 7.10% contrast with a 1 year total shareholder return of 70.96% and a roughly...
NYSE:BEN
NYSE:BENCapital Markets

Assessing Franklin Resources (BEN) Valuation After Its Latest Earnings Surprise

Franklin Resources (BEN) has been back on investors’ radar after its latest quarterly report showed earnings per share coming in ahead of analyst expectations. This has prompted fresh interest in how the asset manager is currently valued. See our latest analysis for Franklin Resources. The recent earnings surprise has come alongside a clear shift in sentiment around the share price, with Franklin Resources posting a 21.43% 90 day share price return and a 46.49% 1 year total shareholder...
NYSE:LPX
NYSE:LPXForestry

A Look At Louisiana-Pacific (LPX) Valuation As Mixed Returns Temper Recent Share Moves

Why Louisiana-Pacific Is On Investors’ Radar Today Louisiana-Pacific (LPX) is drawing attention after recent share moves, with the stock up about 1.4% over the past day but showing mixed performance over the past week and month. See our latest analysis for Louisiana-Pacific. The 1-day share price return of 1.45% comes after a softer patch. The 30-day share price return of 5.10% and 1-year total shareholder return decline of 14.97% signal that shorter term momentum has cooled, despite stronger...
NYSE:TMO
NYSE:TMOLife Sciences

Thermo Fisher’s TacroType Test Adds Precision Medicine Angle To TMO Story

Thermo Fisher Scientific (NYSE:TMO) has launched its TacroType Pharmacogenetic Test for transplant patients. The test is designed to help clinicians personalize tacrolimus dosing using a patient’s genetic profile. This product aims to support more tailored transplant care and potentially improve post transplant management. Thermo Fisher Scientific enters this launch with its shares at $520.12 and a value score of 4, along with mixed recent returns. The stock is up 1.0% over the past week,...